Ganesh E. Phad

Ganesh E. Phad

Auto-generated profile, based on publicly available information

Ganesh E. Phad

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Nature Immunology
Verified
Journal Article
Open access
PDF file
GPGanesh E. Phad
Ganesh E. Phad
DPDora Pinto
Dora Pinto
MFMathilde Foglierini
Mathilde Foglierini
MAMurodzhon Akhmedov
Murodzhon Akhmedov
Riccardo Lorenzo RossiRiccardo Lorenzo Rossi
Riccardo Lorenzo Rossi
ALAntonio Lanzavecchia
Antonio Lanzavecchia
Memory B cells persist for a lifetime and rapidly differentiate into antibody-producing plasmablasts and plasma cells upon antigen re-encounter. The clonal relationship and evolution of memory B cells and circulating plasmablasts is not well understood. Using single-cell sequencing combined with isolation of specific antibodies, we found that in two healthy donors, the memory B cell repertoire was dominated by large IgM, IgA and IgG2 clonal families, whereas IgG1 families, including those specific for recall antigens, were of small size. Analysis of multiyear samples demonstrated stability of memory B cell clonal families and revealed that a large fraction of recently generated plasmablasts was derived from long-term memory B cell families and was found recurrently. Collectively, this study provides a systematic description of the structure, stability and dynamics of the human memory B cell pool and suggests that memory B cells may be active at any time point in the generation of plasmablasts.

10 November 2014 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
FKFlorian Klein
Florian Klein
LNLilian Nogueira
Lilian Nogueira
YNYoshiaki Nishimura
Yoshiaki Nishimura
GPGanesh Phad
Ganesh Phad
AWAnthony P. West
Anthony P. West
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Antibody-mediated immunotherapy is effective in humanized mice when combinations of broadly neutralizing antibodies (bNAbs) are used that target nonoverlapping sites on the human immunodeficiency virus type 1 (HIV-1) envelope. In contrast, single bNAbs can control simian–human immunodeficiency virus (SHIV) infection in immune-competent macaques, suggesting that the host immune response might also contribute to the control of viremia. Here, we investigate how the autologous antibody response in intact hosts can contribute to the success of immunotherapy. We find that frequently arising antibodies that normally fail to control HIV-1 infection can synergize with passively administered bNAbs by preventing the emergence of bNAb viral escape variants.

1 December 2012 in Journal of Immunological Methods
Verified
Journal Article
Closed access
CSChristopher Sundling
Christopher Sundling
GPGanesh Phad
Ganesh Phad
IDIyadh Douagi
Iyadh Douagi
MNMarjon Navis
Marjon Navis
GHGunilla B. Karlsson Hedestam
Gunilla B. Karlsson Hedestam

15 April 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CSChristopher Sundling
Christopher Sundling
ZZZhenhai Zhang
Zhenhai Zhang
GPGanesh E Phad
Ganesh E Phad
ZSZizhang Sheng
Zizhang Sheng
YWYimeng Wang
Yimeng Wang
GHGunilla Karlsson Hedestam
Gunilla Karlsson Hedestam
The nonhuman primate model is important for preclinical evaluation of prophylactic and therapeutic intervention strategies. The recent description of the rhesus macaque germline Ig loci and establishment of a database of germline gene segments offer improved opportunities to delineate Ig gene usage in the overall B cell repertoire as well as in response to vaccination. We applied 454-pyrosequencing and single-cell RT-PCR of bulk and sorted memory B cells, respectively, to investigate IGHV gene segment expression in rhesus macaques. The two methods gave remarkably concordant results and identified groups of gene segments that are frequently or rarely used. We further examined the VH repertoire of Ag-specific memory B cells induced by immunization with recombinant HIV-1 envelope glycoproteins, an important vaccine component. We demonstrate that HIV-1 envelope glycoprotein immunization activates a highly polyclonal response composed of most of the expressed VH gene segments, illustrating the considerable genetic diversity of responding B cells following vaccination.

15 May 2016 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
NMNavid Madani
Navid Madani
APAmy M. Princiotto
Amy M. Princiotto
DEDavid Easterhoff
David Easterhoff
TBTodd Bradley
Todd Bradley
KLKan Luo
Kan Luo
JSJoseph Sodroski
Joseph Sodroski
The human immunodeficiency virus (HIV-1) envelope glycoproteins (Env) mediate virus entry through a series of complex conformational changes triggered by binding to the receptors CD4 and CCR5/CXCR4. Broadly neutralizing antibodies that recognize conserved Env epitopes are thought to be an important component of a protective immune response. However, to date, HIV-1 Env immunogens that elicit broadly neutralizing antibodies have not been identified, creating hurdles for vaccine development. Small-molecule CD4-mimetic compounds engage the CD4-binding pocket on the gp120 exterior Env and induce Env conformations that are highly sensitive to neutralization by antibodies, including antibodies directed against the conserved Env region that interacts with CCR5/CXCR4. Here, we show that CD4-mimetic compounds sensitize primary HIV-1 to neutralization by antibodies that can be elicited in monkeys and humans within 6 months by several Env vaccine candidates, including gp120 monomers. Monoclonal antibodies directed against the gp120 V2 and V3 variable regions were isolated from the immunized monkeys and humans; these monoclonal antibodies neutralized a primary HIV-1 only when the virus was sensitized by a CD4-mimetic compound. Thus, in addition to their direct antiviral effect, CD4-mimetic compounds dramatically enhance the HIV-1-neutralizing activity of antibodies that can be elicited with currently available immunogens. Used as components of microbicides, the CD4-mimetic compounds might increase the protective efficacy of HIV-1 vaccines. IMPORTANCE Preventing HIV-1 transmission is a high priority for global health. Eliciting antibodies that can neutralize transmitted strains of HIV-1 is difficult, creating problems for the development of an effective vaccine. We found that small-molecule CD4-mimetic compounds sensitize HIV-1 to antibodies that can be elicited in vaccinated humans and monkeys. These results suggest an approach to prevent HIV-1 sexual transmission in which a virus-sensitizing microbicide is combined with a vaccine.

15 June 2015 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GPGanesh E Phad
Ganesh E Phad
NBNéstor Vázquez Bernat
Néstor Vázquez Bernat
YFYu Feng
Yu Feng
JIJidnyasa Ingale
Jidnyasa Ingale
PMPaola Andrea Martinez Murillo
Paola Andrea Martinez Murillo
GHGunilla Karlsson Hedestam
Gunilla Karlsson Hedestam
Isolation of mAbs elicited by vaccination provides opportunities to define the development of effective immunity. Ab responses elicited by current HIV-1 envelope glycoprotein (Env) immunogens display narrow neutralizing activity with limited capacity to block infection by tier 2 viruses. Intense work in the field suggests that improved Env immunogens are forthcoming, and it is therefore important to concurrently develop approaches to investigate the quality of vaccine-elicited responses at a higher level of resolution. In this study, we cloned a representative set of mAbs elicited by a model Env immunogen in rhesus macaques and comprehensively characterized their genetic and functional properties. The mAbs were genetically diverse, even within groups of Abs targeting the same subregion of Env, consistent with a highly polyclonal response. mAbs directed against two subdeterminants of Env, the CD4 binding site and V region 3, could in part account for the neutralizing activity observed in the plasma of the animal from which they were cloned, demonstrating the power of mAb isolation for a detailed understanding of the elicited response. Finally, through comparative analyses of mAb binding and neutralizing capacity of HIV-1 using matched Envs, we demonstrate complex relationships between epitope recognition and accessibility, highlighting the protective quaternary packing of the HIV-1 spike relative to vaccine-induced mAbs.